Your session is about to expire
← Back to Search
VIP152 + Venetoclax + Prednisone for Blood Cancers
Study Summary
This trial is testing a new combination of drugs to treat aggressive blood cancers that have not responded to other treatments, or have returned after treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have another active cancer that could interfere with treatment.I do not have heart problems like failure, chest pain, or irregular heartbeat.I currently have an active CMV or COVID-19 infection.My heart function is within normal limits.I do not have any active or recent major infections.My organs and bone marrow are working well.I am 18 years old or older.I have hepatitis but my viral load is undetectable.I need certain medications before I can start the study drug.I recently had a stem cell transplant or have active graft-versus-host disease.I am still experiencing side effects from previous cancer treatments.I do not have serious liver disease or active hepatitis B or C.I have not recently had treatments with radio- or toxin-immunoconjugates.I cannot take medications by mouth due to absorption issues.My cancer is a type of lymphoid malignancy confirmed by lab tests.I can take care of myself but might not be able to do heavy physical work.I have recently undergone chemotherapy, targeted therapy, or received anti-cancer antibodies.My aggressive B-cell lymphoma or PTCL has returned or is not responding to treatment.
- Group 1: 1/Phase 1: Arm 1 Dose Escalation
- Group 2: 2/Phase 2: Arm 2 Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can new patients still sign up to participate in this research?
"This particular clinical trial is not recruiting patients at this time. Based on the information provided by clinicaltrials.gov, which includes the posting date (11/23/2022) and last update (11/17/2022), it can be inferred that the study has completed recruitment. There are 4226 other trials open for patient enrollment currently."
What are the most important goals of this medical study?
"The primary outcome of this clinical trial is to monitor adverse events over a period of time. Secondary objectives include progression-free survival (PFS), time to response (TTR), and duration of response (DOR)."
Share this study with friends
Copy Link
Messenger